New drug duo shows promise against rare eye cancer
NCT ID NCT04552223
First seen Feb 16, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tested whether combining two immunotherapy drugs, nivolumab and relatlimab, could shrink tumors in people with metastatic uveal melanoma, a rare eye cancer that has spread. 27 adults who had not received certain prior treatments took part. The goal was to see how many patients had their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.